Literature DB >> 15312816

Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment.

Andreas Fellgiebel1, Thomas Siessmeier, Armin Scheurich, Georg Winterer, Peter Bartenstein, Lutz G Schmidt, Matthias J Müller.   

Abstract

BACKGROUND: Mild cognitive impairment is considered to be a transitional stage between normal aging and dementia. Phosphorylated tau protein in cerebrospinal fluid and even more decrements of cerebral glucose metabolism in parietal, temporal, or cingulate regions have shown favorable specificity for the diagnosis of Alzheimer dementia and could be useful supplementary tools to determine Alzheimer pathology in early stages.
METHODS: We measured cerebrospinal fluid tau phosphorylated at threonine 181 protein, cerebrospinal fluid total tau, and cerebral glucose metabolism using 18F-fluoro-2-deoxy-D-glucose positron emission tomography in 16 patients with mild cognitive impairment and age-matched control subjects.
RESULTS: Alzheimer-typical patterns of cerebral glucose metabolism were significantly related to elevated phosphorylated tau levels (p =.009) but not to elevated total tau levels. In six of seven mild cognitive impairment patients with increased phosphorylated tau concentrations, Alzheimer disease-typical positron emission tomography patterns were found. Phosphorylated tau measurement separated patients with and without Alzheimer disease-typical positron emission tomography findings with a sensitivity of 85.7% and a specificity of 88.9%.
CONCLUSIONS: Unlike total tau levels, elevated phosphorylated tau levels were strictly related to Alzheimer-typical patterns of cerebral glucose metabolism in mild cognitive impairment patients. The results can be interpreted as validation of phosphorylated tau measurements for detecting Alzheimer disease in mild cognitive impairment patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312816     DOI: 10.1016/j.biopsych.2004.05.014

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study.

Authors:  Nabil Maalikjy Akkawi; B Borroni; C Agosti; M Magoni; M Broli; A Pezzini; A Padovani
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.

Authors:  Sönke Arlt; Stefanie Brassen; Holger Jahn; Florian Wilke; Martin Eichenlaub; Ivayla Apostolova; Fabian Wenzel; Frank Thiele; Stewart Young; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-14       Impact factor: 9.236

Review 3.  PET/CT in diagnosis of dementia.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

4.  The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Authors:  N Maritza Dowling; Sterling C Johnson; Carey E Gleason; William J Jagust
Journal:  Neuroimage       Date:  2014-10-29       Impact factor: 6.556

Review 5.  ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Nadja Smailagic; Marco Vacante; Chris Hyde; Steven Martin; Obioha Ukoumunne; Christos Sachpekidis
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

6.  Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease.

Authors:  Philipp A Thomann; Elmar Kaiser; Peter Schönknecht; Johannes Pantel; Marco Essig; Johannes Schröder
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

7.  Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation.

Authors:  Linn Hege Nilsen; Caroline Rae; Lars M Ittner; Jürgen Götz; Ursula Sonnewald
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-23       Impact factor: 6.200

8.  Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Authors:  Lisa Mosconi; Susan De Santi; Miroslaw Brys; Wai H Tsui; Elizabeth Pirraglia; Lidia Glodzik-Sobanska; Kenneth E Rich; Remigius Switalski; Pankaj D Mehta; Domenico Pratico; Ray Zinkowski; Kay Blennow; Mony J de Leon
Journal:  Biol Psychiatry       Date:  2007-08-27       Impact factor: 13.382

9.  Relationships between biomarkers in aging and dementia.

Authors:  W J Jagust; S M Landau; L M Shaw; J Q Trojanowski; R A Koeppe; E M Reiman; N L Foster; R C Petersen; M W Weiner; J C Price; C A Mathis
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

Review 10.  Diagnosis and biomarkers of predementia in Alzheimer's disease.

Authors:  Orestes V Forlenza; Breno S Diniz; Wagner F Gattaz
Journal:  BMC Med       Date:  2010-12-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.